In non-small cell lung cancer, researchers are testing personalized mRNA vaccines such as V940/mRNA-4157 after surgery in combination with pembrolizumab. These studies focus on people with resected disease, where the aim is to train the immune system against tumor-specific neoantigens and reduce recurrence risk. This is an active Phase 3 research direction, not routine treatment.
A notable finding from recent research is that zongertinib, a selective HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation → tyrosine kinase inhibitor, achieved an objective response rateThe proportion of patients whose cancer shrinks or disappears after treatment.Click for full explanation → of 76% and a median progression-free survival of 14.4 months in patients newly diagnosed with HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation →-mutant NSCLC, substantially outperforming the roughly 30% response rateThe proportion of patients whose cancer shrinks or disappears after treatment.Click for full explanation → and less than 7 months duration seen with chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation →. Phase 3 trials are comparing immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → combinations: a study (NCT04267848) is testing immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → added to standard chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → in NSCLC, and another (NCT06312137) is evaluating sacituzumab tirumotecan combined with pembrolizumab in resectable NSCLC not achieving pathological complete response. A Phase 2 study (NCT07329322) is examining sacituzumab tirumotecan with osimertinib as neoadjuvant treatment for resectable EGFR-mutated NSCLC. KRASOne of the most common cancer-driving mutations, found in lung, colon, and pancreatic cancers.Click for full explanation → G12C-directed therapy is being evaluated in unresectable Stage III NSCLC (NCT05398094). T cell receptor-based therapies engineered to target KRASOne of the most common cancer-driving mutations, found in lung, colon, and pancreatic cancers.Click for full explanation → G12D mutationsA change in DNA sequence that can drive cancer development.Click for full explanation → are in Phase 1 testing (NCT06218914). For SCLC, a DLL3-targeted chimeric antigen receptorA type of immunotherapy that genetically engineers a patient's own T cells to recognise and destroy cancer cells.Click for full explanation → T cell (CAR-TA type of immunotherapy that reprograms a patient's own T cells to attack cancer.Click for full explanation →) therapy is in early Phase 1 evaluation (NCT07249879). Research on circulating tumor cells as predictors of response to neoadjuvant chemoimmunotherapy is ongoing, as is work on exosomal RNA fragments as non-invasive diagnostic biomarkersA measurable biological signal used to detect disease or predict treatment response.Click for full explanation →. Overcoming primary immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → resistance in tumors with STK11 mutationsA change in DNA sequence that can drive cancer development.Click for full explanation → is another active area of investigation.
Where the evidence stands
Targeted therapiesDrugs that block specific molecules that cancer cells need to grow.Click for full explanation → for NSCLC with actionable mutationsA change in DNA sequence that can drive cancer development.Click for full explanation → in EGFR, ALK, BRAF, KRASOne of the most common cancer-driving mutations, found in lung, colon, and pancreatic cancers.Click for full explanation → G12C, RET, and HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation → have the strongest evidence base and are standard of care when applicable. ImmunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → alone or with chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → has robust Phase 3 support for NSCLC without actionable mutationsA change in DNA sequence that can drive cancer development.Click for full explanation → and for SCLC. The pipeline for overcoming acquired resistance after EGFR inhibitor therapy is active at Phase 1 and Phase 2. Newer antibody-drug conjugates are moving through Phase 2 and Phase 3 trials. CAR-TA type of immunotherapy that reprograms a patient's own T cells to attack cancer.Click for full explanation → and T cell receptor-based cellular therapies are in very early Phase 1 exploration. Combination immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → and neoadjuvant strategies are being refined across multiple settings. BiomarkerA measurable biological signal used to detect disease or predict treatment response.Click for full explanation →-based detection tools are still in the research and validation phase.
What this means for people affected
Lung cancer, once treated primarily with chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation →, now has a broad landscape of targeted therapiesDrugs that block specific molecules that cancer cells need to grow.Click for full explanation → for patients whose tumors carry specific mutationsA change in DNA sequence that can drive cancer development.Click for full explanation →. Molecular testing at diagnosis has become an essential step that can unlock highly effective treatment options. For those without actionable mutationsA change in DNA sequence that can drive cancer development.Click for full explanation →, immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → has meaningfully extended survival in many cases. Small cell lung cancer remains challenging, though immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → combinations have shown benefit. The research pace is fast, with multiple active trials testing how to extend disease control after resistance develops and how to bring cellular therapies from early investigation into clinical use.
Last updated May 22, 2026
Recent research findings
Understanding evidence levels▼
PreclinicalLab or cell studies — no human data yet.
Animal StudyResults in animals only — may not apply to humans.
Phase 1 TrialFirst-in-human safety testing in small groups.
Phase 2 TrialEarly effectiveness testing in a larger group.
Phase 3 TrialLarge controlled trial — the strongest trial evidence.
Observational StudyPatterns observed in populations — not a controlled trial.
ReviewSummary analysis of multiple existing studies.
Meta-AnalysisStatistical pooling of results from multiple studies.
◆ Notable findingA noteworthy finding, often from later-stage research, but below the higher significance thresholds.Phase 3 TrialLarge controlled trial comparing treatments. The strongest level of trial evidence.Published: August 15, 2026
Cost-effectiveness of sugemalimab plus chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → for lung cancer
Researchers analyzed the cost-effectiveness of sugemalimab plus chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → compared to chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → alone for treating metastatic non-small-cell lung cancer. They used data from a clinical trialA research study that tests a medical intervention in human volunteers.Click for full explanation → and estimated that the treatment may not be cost-effective, but could be with price reductions or patient assistance programs. The results are based on a 10-year time horizon and a Chinese healthcare perspective.
Why it matters: This finding could influence treatment decisions and healthcare policies for patients with metastatic non-small-cell lung cancer.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Published: August 14, 2026
Combining ChemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → and ImmunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → for Lung Cancer
Researchers treated a patient with advanced non-small cell lung cancer using a combination of chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → and an immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → drug called pembrolizumab. The treatment led to a significant reduction in metastatic lesions, but this was a single case and more research is needed to confirm the results.
Why it matters: This finding may lead to new treatment options for patients with advanced non-small cell lung cancer.
A single case report, further clinical trials are warranted to validate this approach.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Published: August 14, 2026
New Blood Test May Help Predict Lung Cancer Outcomes
Researchers looked at blood tests from 64 patients with advanced lung cancer to see if a certain ratio of two substances could predict how well they would do with treatment. They found that a high ratio was linked to shorter survival and less time without the cancer getting worse. This is an early study and needs more testing to confirm its findings.
Why it matters: This finding could help doctors better understand which patients are at higher risk and might benefit from closer monitoring or different treatment plans.
This study was small and looked back at past cases, so more research is needed to confirm its findings.
Animal StudyResults in animals only. May or may not apply to humans.Published: August 14, 2026
Researchers Identify Potential Target for Lung Cancer Prevention
Scientists developed a way to study inflammation in early lung cancer and found that a specific enzyme, caspase-1, might play a role in the disease's development. They tested a combination therapy that blocked this enzyme and another molecule involved in inflammation, and found some promising results in a mouse model. However, more research is needed to confirm these findings.
Why it matters: This discovery could lead to new strategies for preventing lung cancer from developing or progressing.
Efficacy
We observed significant reduction in lung cancer, including complete ablation of tumor incidence in nearly 20% of KPS mice.
✦ Significant findingA meaningful signal from later-stage research, or a strong phase 2 result that stands out from routine findings.Phase 2 TrialTests early effectiveness in a larger group after phase 1 safety is established.Published: August 14, 2026
New Imaging Test May Help Predict Lung Cancer Treatment Response
Researchers used a special imaging test to see how well lung cancer patients responded to treatment. They found that the test could predict how well patients would do and how long they would be free of cancer progression. However, more research is needed to confirm these findings.
Why it matters: This finding could help doctors make more informed decisions about treatment for patients with non-small cell lung cancer.
Efficacy
SUV was an independent predictor of immune response (OR 15.6, 95% CI 1.419-172.2, P = 0.025).
This study was conducted at a single center and involved a relatively small number of patients.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Published: August 14, 2026
Malnutrition Linked to Poorer Survival in Lung Cancer Patients
Researchers studied 374 lung cancer patients to see how malnutrition affects their survival. They found that patients with severe malnutrition had poorer survival rates and lower muscle mass. The study suggests that malnutrition is a significant concern for lung cancer patients.
Why it matters: This finding highlights the importance of nutritional assessment and support for lung cancer patients.
Efficacy
Severe GLIM-defined malnutrition was associated with increased one-year mortality in unadjusted analysis (HR 4.31, 95% CI 2.73-6.80) and after adjustment for age, sex, BMI, and ECOG performance status (HR 3.32, 95% CI 1.96-5.61).
✦ Significant findingA meaningful signal from later-stage research, or a strong phase 2 result that stands out from routine findings.Meta-AnalysisStatistical pooling of results from multiple studies.Published: August 14, 2026
Comparing ChemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → Options for Lung Cancer Patients
Researchers compared two types of chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation →, cisplatin and carboplatin, in patients with completely resected non-small cell lung cancer. They found no significant difference in survival outcomes between the two treatments. More studies are needed to confirm these findings.
Why it matters: This finding may help doctors choose the best chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → option for patients who cannot receive cisplatin.
Lab StudyLaboratory experiments on cells or tissue. No human or animal data.Published: August 14, 2026
SMARCA4 Alterations in Cancer: New Insights
Researchers analyzed 68,920 tumor samples to understand SMARCA4 alterations in different types of cancer. They found distinct patterns of genomic complexity and co-occurring alterations based on the SMARCA4 alteration's allelic state and class. This may help identify patients who could benefit from emerging therapies.
Why it matters: This finding could help doctors select patients for new treatments targeting SMARCA4 alterations.
Efficacy
Patients with monoallelic class 2 SMARCA4 alterations and preserved BRG1 expression saw clinical benefit, including one who attained a complete response.
Lab StudyLaboratory experiments on cells or tissue. No human or animal data.Published: August 14, 2026
New Approach to Targeting Cancer Protein Shows Promise in Lung Cancer
Researchers developed a new way to break down a faulty protein that helps lung cancer grow. In lab experiments, this approach led to the regression of lung cancer tumors. However, the tumors eventually came back due to resistance.
Why it matters: This finding could lead to new treatments for lung cancer and help scientists understand how to overcome resistance to these treatments.
The study was conducted in a lab setting and used a mouse model, so its results may not directly apply to humans.
Lab StudyLaboratory experiments on cells or tissue. No human or animal data.Published: August 14, 2026
HDAC1 linked to lung cancer progression
Researchers studied how a protein called HDAC1 affects lung cancer cells. They found that HDAC1 might contribute to lung cancer growth by changing the behavior of another protein called β-catenin. However, more research is needed to fully understand this connection.
Why it matters: This finding could help scientists develop new treatments for lung cancer by targeting the HDAC1/β-catenin pathway.
The study was conducted in lab experiments using lung cancer cell lines and did not involve human patients.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Published: August 14, 2026
Disparities in Lung Cancer Testing Remain Despite Guidelines
Researchers analyzed data from over 144,000 lung cancer patients to see how often they got a specific test called EGFR mutationA change in DNA sequence that can drive cancer development.Click for full explanation → testing. They found that testing rates varied by factors like race, income, and where patients got their care. Many patients didn't get the test, and disparities exist in how testing is done.
Why it matters: This finding highlights the need for better access to and coordination of lung cancer care, particularly for patients from underrepresented groups.
✦ Significant findingA meaningful signal from later-stage research, or a strong phase 2 result that stands out from routine findings.Phase 2 TrialTests early effectiveness in a larger group after phase 1 safety is established.Published: August 14, 2026
New Treatment Combination Shows Promise for Lung Cancer Patients
Researchers tested a combination of two medications, durvalumab and olaparib, as maintenance therapy for patients with a type of lung cancer called small-cell lung cancer. They found that some patients responded well to the treatment, but more research is needed to understand who will benefit. The study suggests that DNA hypomethylation may be a factor in who responds to this treatment.
Why it matters: This finding could help doctors identify which patients are most likely to benefit from this treatment combination.
Efficacy
The combination regimen demonstrated an objective response rate of 73.3% and a median overall survival of 14.6 months.
A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRASOne of the most common cancer-driving mutations, found in lung, colon, and pancreatic cancers.Click for full explanation → G12D MutationA change in DNA sequence that can drive cancer development.Click for full explanation →
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
MOONRAY-01, A Study of LY3962673 in Participants With KRASOne of the most common cancer-driving mutations, found in lung, colon, and pancreatic cancers.Click for full explanation → G12D-Mutant Solid Tumors
T Cell Receptor ImmunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → for Patients With Metastatic Non-Small Cell Lung Cancer
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
Testing the Addition of a Type of Drug Called ImmunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → to the Usual ChemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
